Peripheral Vascular Disorders
Conference Coverage
VIDEO: Rivaroxaban plus aspirin cut cardiovascular events in stable patients
BARCELONA – The COMPASS trial produced “unambiguous results that should change guidelines and the management of stable coronary artery disease,”...
Conference Coverage
CANTOS sings of novel strategy for cardiovascular, cancer prevention
BARCELONA – Targeted anti-inflammatory therapy with canakinumab showed diverse clinical benefits.
Latest News
PVC phlebitis rates varied widely, depending on assessment tool
Rates also varied within individual instruments because they included several possible case definitions.
From the Journals
New-onset AF after aortic valve replacement did not affect long-term survival
New-onset atrial fibrillation after AVR did not affect long-term survival when sinus rhythm was restored before discharge.
Conference Coverage
ANCA-associated vasculitis appears to increase risk of stroke, death
MADRID – But there was no higher risk for myocardial infarction.
Conference Coverage
Lithoplasty tames heavily calcified coronary lesions
PARIS – Novel pre-PCI “lithotripsy inside a balloon” technology is also approved for PAD.
Conference Coverage
Bilateral cellulitis on legs? Think venous stasis dermatitis
If a patient presents with bilateral cellulitis on both legs, think venous stasis dermatitis, which is the number one misdiagnosis of cellulitis...
Conference Coverage
Major bleeding deaths may outweigh VTE risk in older cancer patients
Anticoagulation should be considered, carefully, on a patient-by-patient basis.
News
FDA approves betrixaban for VTE prophylaxis
An orally administered agent has been approved for VTE prophylaxis in at risk hospitalized patients.
From the Journals
Cancer, heart disease increase MRSA mortality
Despite advancement in antimicrobial treatment, MRSA mortality rates have changed little in 9 years.
Conference Coverage
High readmits after peripheral arterial procedures
WASHINGTON – Why tying hospital reimbursement to readmissions won’t work in this case.